Puma Biotech (PBYI), Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
- Futures muted after S&P 500, Dow hit record closing highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Dollar heads for second weekly loss on Fed's lower-for-longer stance
- Apple (AAPL) May Scrap iPhone Mini Next Year, New Lineup to Focus on Camera Quality, Says Top Analyst
- Oil rises above $67 in fifth day of gains on demand hopes
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX® (neratinib) within Europe, Turkey, Middle East and Africa. The amended agreement extends Pierre Fabre’s commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.
Under the terms of the amendment, Puma will receive an upfront payment of $50 million, as well as additional regulatory and sales-based milestone payments that could add up to an additional $240 million. These milestones will be based solely on regulatory and sales achievements in Greater China. In addition, Puma will receive significant double-digit tiered royalties on the sales of NERLYNX in Greater China.
Concomitantly, Puma and CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing drug candidates in China and North Asia, have mutually agreed to terminate the license agreement to commercialize NERLYNX (neratinib) in Greater China. Puma has agreed to pay CANbridge a one-time termination fee of $20 million to return all rights to neratinib in Greater China back to Puma. Additionally, Puma has agreed to dismiss the arbitration demand it filed on July 28, 2020 against CANbridge related to the parties’ 2018 license agreement, and as part of the settlement, CANbridge has agreed to dismiss its counterclaims against Puma. Such settlement is limited to claims that arose in arbitration, or could have been raised in arbitration, as well as claims arising under the to be terminated license agreement.
Alan H. Auerbach, Chief Executive Officer and President of Puma, said, “We are pleased to extend our collaboration with Pierre Fabre into the Greater China region. Pierre Fabre is well equipped with existing infrastructure to make NERLYNX a success in mainland China and Pierre Fabre plans to make NERLYNX available to breast cancer patients in mainland China in the second quarter of this year.”
“We are excited about the opportunity to provide NERLYNX to Chinese patients with early stage HER2-positive breast cancer,” said Jean-Luc Lowinsky, Chief Executive Officer, Pierre Fabre Pharmaceuticals. “Our oncology team based in Shanghai is fully committed to start the commercialization of NERLYNX, which perfectly complements our existing NAVELBINE chemotherapy in breast and lung cancers.”
Neratinib is approved in the United States for both the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and for adult patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine in patients who have received two or more prior anti-HER2 based regimens and is marketed in the United States as NERLYNX® (neratinib) tablets.
About HER2-Positive Breast Cancer
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AVEO Oncology (AVEO) Adds Kevin Cullen, M.D. to Board
- Analysis: Countries seek more Moderna, Pfizer/BioNTech COVID-19 shots as concerns mount over rival vaccines
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!